Zika and the blood supply: A work in progress

Archives of Pathology and Laboratory Medicine

Volumn 141, Issue 1, 2017, Pages 85-92

  Katz, Louis M ^a,b   Rossmann, Susan N ^c  

^a America's Blood Centers   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA;

ADVERSE EFFECTS; BLOOD; BLOOD DONOR; BLOOD TRANSFUSION; COMMUNICABLE DISEASES, EMERGING; DONOR SELECTION; FOOD AND DRUG ADMINISTRATION; GENETICS; HOST PATHOGEN INTERACTION; HUMAN; LEGISLATION AND JURISPRUDENCE; PHYSIOLOGY; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STANDARDS; TRANSMISSION; UNITED STATES; VIROLOGY; ZIKA VIRUS; ZIKA VIRUS INFECTION;

BLOOD DONORS; BLOOD TRANSFUSION; COMMUNICABLE DISEASES, EMERGING; DONOR SELECTION; GUIDELINES AS TOPIC; HOST-PATHOGEN INTERACTIONS; HUMANS; RISK ASSESSMENT; RISK FACTORS; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; ZIKA VIRUS; ZIKA VIRUS INFECTION;

EID: 85008311415     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2016-0430-RA     Document Type: Article

References (73)

1. Eder A, Muniz LA. Allogeneic and autologous blood donor selection. In: Fung MK, Grossman BJ, Hillyer CD, Westhoff CM, eds. Technical Manual. 18th ed. Bethesda, MD: AABB Press; 2014:117-134.
2. Biggerstaff BJ, Petersen LR. Esimtated risk of West Nile virus transmission through blood transfusion during an epidemic in Queens, New York City. Transfusion. 2002;42(8):1019-1026.
3. Centers for Disease Control and Prevention. Public health dispatch: West Nile virus infection in organ donor and transplant recipients-Georgia and Florida, 2002. MMWR Morb Mortal Wkly Rep. 2002;51(35):790.
4. Iwamoto M, Jernigan DB, Guasch A, et al, Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med. 2003;348(22): 2196-2203.
5. Glynn SA, Busch MP, Dodd RY, et al. Emerging infectious agents and the nation's blood supply: responding to potential threats in the 21st century. Transfusion. 2013;53(2):438-454.
6. Stramer SL, Hollinger FB, Katz LM, et al. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion. 2009;49(suppl 2):1S-29S.
7. Duffy MR, Chen TH, Hancock WT, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med. 2009;360(24):2536-2543.
8. Rasmussen SA, Jamieson DJ, Honein MA, Petersen LR. Zika virus and birth defects-reviewing the evidence for causality. N Engl J Med. 2016;374(20):1981-1987.
9. Cao-Lormeau VM, Blake A, Mons S, et al. Guillain-Barre syndrome outbreak associated with Zika virus infection in French Polynesia: A case-control study. Lancet. 2016;387(10027):1531-1539.
10. Regan DM, Markowitz MA. Association bulletin 16-04: Zika, dengue and chikungunya viruses. AABB Web site. http://www.aabb.org/programs/publications/bulletins/Documents/ab16-04.pdf. Published March 1, 2016. Accessed August 20, 2016.
11. Regan DM and Markowitz MA. Association bulletin 16-06: blood center and public health actions to reduce the risk of Zika virus transfusion transmission. AABB Web site. http://www.aabb.org/programs/publications/bulletins/Documents/ab16-06.pdf. Published August 16, 2016. Accessed August 20, 2016.
12. US Food and Drug Administration. Recommendations for donor screening, deferral, and product management to reduce the risk of transfusiontransmission of Zika virus: guidance for industry. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/UCM486360.pdf. Published February 2016. Accessed September 11, 2016.
13. US Food and Drug Administration. Questions and answers regarding ''recommendations for donor screening, deferral, and product management to reduce the risk of transfusion-transmission of Zika virus: Guidance for Industry''. http: //www. fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/UCM490435. pdf. Published March 2016. Accessed September 6, 2016.
14. US Food and Drug Administration. Donor screening recommendations to reduce the risk of transmission of Zika virus by human cells, tissues, and cellular and tissue-based products: guidance for industry. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/UCM488582.pdf. Accessed September 6, 2016.
15. US Food and Drug Administration. Revised recommendations for reducing the risk of Zika virus transmission by blood and blood components: guidance for industry. ht tp://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/UCM518213. pdf. Published August 2016. Accessed September 9, 2016.
16. Dick GWA, Kitchen SF, Haddow AJ. Zika virus (1): isolations and serological specificity. Trans R Soc Trop Med Hyg. 1952;46(5):509-520.
17. Lazear HM, Diamond MS. Zika virus: new clinical syndromes and its emergence in the Western hemisphere. J Virol. 2016;90(10):4864-4875.
18. Simpson DIH. Zika virus infection in man. Trans R Soc Trop Med Hyg. 1964;58(4):335-337.
19. Aubry M, Teissier A, Roche C, et al. Serosurvey of dengue, Zika and other mosquito-borne viruses in French Polynesia: annual meeting of the American Society of Tropical Medicine and Hygiene; Philadelphia, PA, October 27, 2015 [abstract book]. Am J Trop Med Hyg. 2015;93:231-232. http://www. abstractsonline.com/Plan/ViewAbstract.aspxsKey2e5199c4-aceb-4d61-8769-342586917c5a&cKey74ffe328-3a83-4f28-84c6-5656971501c8&mKey% 7bAB652FDF-0111-45C7-A5E5-0BA9D4AF5E12%7d. Accessed August 19, 2016.
20. Oehler E, Watrin L, Larre P, et al. Zika virus infection complicated by Guillain-Barre syndrome-case report, French Polynesia, December 2013. Euro Surveill. 2014;19(9): pii: 20720.
21. Faria NR, Azevedo RSS, Kraemer MUG, et al. Zika virus in the Americas: early epidemiological and genetic findings. Science. 2016;352 (6283):345-349.
22. Zanluca C, de Melo VC, Mosimann AL, et al. First report of autochthonous transmission of Zika virus in Brazil. Mem Inst Oswaldo Cruz. 2015;110(4):569-572.
23. Ministerio da Saude (Brazil). Microcefalia-Ministerio da Saude divulga boletim epidemiológico [in Portuguese]. Updated November 17, 2015. http://portalsaude.saude.gov.br/index.php/cidadao/principal/agencia-saude/20805-ministerio-da-saude-divulga-boletim-epidemiologico. Accessed August 20, 2016.
24. World Health Organization. Zika virus situation reports, 2016. http://www. who.int/emergencies/zika-virus/situation-report/en. Accessed August 20, 2016.
25. Hennessey M, Fischer M, Staples JE. Zika virus spreads to new areas-region of the Americas, May 2015-January 2016. MMWR Morb Mortal Wkly Rep. 2016; 65(3):55-58.
26. US Centers for Disease Control and Prevention. Zika virus: case counts in the US. http://www.cdc.gov/zika/geo/united-states.html http://www.cdc.gov/zika/geo/active-countries.html. Accessed September 9, 2016.
27. US Centers for Disease Control and Prevention. Zika virus: potential range in U.S. http://www.cdc.gov/zika/vector/range.html. Accessed August 20, 2016.
28. US Centers for Disease Control and Prevention. Dengue. http://www.cdc. gov/dengue/index.html. Accessed August 20, 2016.
29. US Centers for Disease Control and Prevention. Chikungunya. http://www. cdc.gov/chikungunya. Accessed August 20, 2016.
30. State of Hawaii, Department of Health. Dengue outbreak, 2015-2016. http://health.hawaii.gov/docd/dengue-outbreak-2015. Accessed August 20, 2016.
31. Florida Department of Health. Press Release. Daily Zika update. http://www.floridahealth.gov/newsroom/2016/08/081816-zika-update.html. Published September 8, 2016. Accessed September 9, 2016.
32. US Centers for Disease Control and Prevention. Transcript for CDC telebriefing: Zika virus update-August 1, 2016. http://www.cdc.gov/media/releases/2016/t0801-zika-update.html. Accessed September 9, 2016.
33. US Food and Drug Administration. Zika virus response updates from FDA. http://www.fda.gov/EmergencyPreparedness/Counterterrorism/MedicalCountermeasures/MCMIssues/ucm485199.htm#blood. Accessed September 9, 2016.
34. Davidson A, Slavinski S, Komoto K, Rakeman J, Weiss D. Suspected female-to-male sexual transmission of Zika virus-New York City, 2016. MMWR Morb Mortal Wkly Rep. 2016;65(28):716-717.
35. Allegheny County Health Department. Health department reports fourth confirmed case of Zika in the county: virus contracted in an isolated lab incident. http://www.achd.net/pr/pubs/2016release/060916-zika.html. Assessed August 20, 2016.
36. Dupont-Rouzeyrol M, Biron A, O'Connor O, Huguon E, Descloux E. Infectious Zika viral particles in breastmilk [letter]. Lancet. 2016;387(10023): 1051.
37. Musso D, Roche C, Nhan TX, Robin E, Teissier A, Cao-Lormeau VM. Detection of Zika virus in saliva. J Clin Virol. 2015;68:53-55.
38. US Centers for Disease Control and Prevention. Media statement. http://www.cdc.gov/media/releases/2016/s0718-zika-utah-investigation.html. Published July 18, 2016. Accessed August 20, 2016.
39. Tavernise S. Zika virus case in Utah baffles health officials. New York Times. July 18, 2016. http://www.nytimes.com/2016/07/19/health/utah-zikacase. html-r0. Accessed August 20, 2016.
40. Franca GVA, Schuler-Faccini L, Oliveira WK, et al. Congenital Zika virus syndrome in Brazil: A case series of the first 1501 livebirths with complete investigation. Lancet. 2016;388(10047):891-897.
41. Garcez PP, Loiola EC, Madiero da Costa R, et al. Zika virus impairs growth in human neurospheres and brain organoids. Science. 2016;352(6287):816-818.
42. Brasil P, Pereira JP, Gabaglia CR, et al. Zika virus infection in pregnant women in Rio de Janeiro-preliminary report [published online ahead of print March 4, 2016]. N Engl J Med. doi: 10.1056/NEJMoa1602412.
43. Johansson MA, Mier-y-Teran-Romero L, Reefhuis J, Gilboa SM, Hills SL. Zika and the risk of microcephaly [published online ahead of print July 7, 2016]. N Engl J Med. doi: 10.1056/NEJMp1605367.
44. Cauchemez S, Besnard M, Bompard P, et al. Association between Zika virus and microcephaly in French Polynesia, 2013-15: A retrospective study. Lancet. 2016;387(10033):2125-2132.
45. Musso D, Nhan T, Robin E, et al. Potential for Zika virus transmission through blood transfusion demonstrated during an outbreak in French Polynesia, November 2013 to February 2014. Euro Surveill. 2014;19(14): pii: 20761.
46. Barjas-Castro ML, Angerami RN, Cunha MS, et al. Probable transfusiontransmission of Zika virus in Brazil. Transfusion. 2016;56(7):1684-1688.
47. Motta IJF, Spencer BR, Cordeiro da Silva SG, et al. Evidence for transmission of Zika virus by platelet transfusion. N Engl J Med. http://www. nejm.org/doi/pdf/10.1056/NEJMc1607262. Published August 17, 2016. Accessed August 21, 2016.
48. Lessler JT, Ott CT, Carcelen AC, et al. Times to key events in the course of Zika infection and their implications: A systematic review and pooled analysis. Bull World Health Organ. doi: 10.2471/BLT.16.174540. Published April 1, 2016. Accessed August 20, 2016.
49. Lustig Y, Mendelson E, Paran N, Melamed S, Schwartz E. Detection of Zika virus RNA in whole blood of imported Zika virus disease cases up to 2 months after symptom onset, Israel, December 2015 to April 2016. Euro Surveill. 2016; 21(26): pii: 30269.
50. Bingham AM, Cone M, Mock V, et al. Comparison of test results for Zika virus RNA in urine, serum, and saliva specimens from persons with travelassociated Zika virus disease-Florida, 2016. MMWR Morb Mortal Wkly Rep. 2016;65(18):475-478.
51. Atkinson B, Hearn P, Afrough B, et al. Detection of Zika virus in semen [letter]. Emerg Infect Dis. 2016;22(5):940.
52. Mansuy JM, Pasquier C, Daudin M, et al. Zika virus in semen of a patient returning from a non-epidemic area. Lancet Infect Dis. 2016;16(8):894-895.
53. Nicastri E, Castilletti C, Liuzzi G, Iannetta M, Capobianchi MR, Ippolito G. Persistent detection of Zika virus RNA in semen for six months after symptom onset in a traveler returning from Haiti to Italy, February 2016. Euro Surveill. 2016;21(32): pii: 30314.
54. Lanteri MC, Lee TH, Wen L, et al. West Nile virus nucleic acid persistence in whole blood months after clearance in plasma: implication for transfusion and transplantation safety. Transfusion. 2014;54(12):3232-3241.
55. Florida Department of Health, Office of Communications. Investigating possible non-travel related case of Zika. http://www.floridahealth.gov/newsroom/2016/07/071916-investigating-possible-non-travel-related-case-zika.html. Published July 19, 2016. Accessed August 18, 2016.
56. Sabino EC, Loureiro P, Lopes ME, et al. Transfusion-transmitted dengue and associated clinical symptoms during the 2012 epidemic in Brazil. J Infect Dis. 2016;213(5):694-702.
57. Chung KW, Basavaraju SV, Mu Y, et al. Declining blood collection and utilization in the United States. Transfusion. 2016;56(9):2184-2192.
58. Carson JL, Guyatt G, Heddle NM, et al. Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage [published online ahead of print October 12, 2016]. JAMA. doi:10.1001/jama.2016.9185.
59. Spencer BR, Stramer S, Dodd R, et al. Survey to estimate donor loss to 14-or 28-day travel deferral for mitigation of CHIKV, DENV and other acute infections. Plenary Abstract P1-030A. Transfusion. 2015;55(suppl 3):3A.
60. Linnen J. NAT assay development: Hologic. Zika Virus Symposium: Blood and HCT/P Safety. June 10, 2016; Washington, DC.
61. Galel S. NAT assay development: Roche. Zika Virus Symposium: Blood and HCT/P Safety. AABB. June 10, 2016; Washington, DC.
62. US Food and Drug Administration. Zika virus EUA information. http://www. fda.gov/EmergencyPreparedness/Counterterrorism/MedicalCountermeasures/MCMLegalRegulatoryandPolicyFramework/ucm182568.htm#zika. Accessed September 11, 2016.
63. Kuehnert MJ, Basavaraju SV, Moseley RR, et al. Screening of blood donations for Zika virus infection-Puerto Rico, April 3-June 11, 2016. MMWR Morb Mortal Wkly Rep. 2016;65(24):627-628.
64. Zika virus biovigilance network. AABB Web site. http://www.aabb.org/research/hemovigilance/Pages/zika.aspx. Accessed September 9, 2016.
65. Benjamin R. Pathogen inactivation of Zika virus using the INTERCEPT blood system. Zika Virus Symposium: Blood and HCT/P Safety. AABB. June 10, 2016; Washington, DC.
66. Aubrey M, Richard V, Green J, Broult J, Musso D. Inactivation of Zika virus in plasma with amotosalen and ultraviolet A illumination. Transfusion. 2015;56 (1):33-40.
67. Goodrich R. Measuring effectiveness of Mirasol PRT against emerging agents: from A to Z. Zika Virus Symposium: Blood and HCT/P Safety. AABB. June 10, 2016; Washington, DC.
68. U.S. Department of Health and Human Services. Organ Procurement and Transplantation Network. Guidance on zika virus. Organ Procurement and Transplantation Network. https://optn.transplant.hrsa.gov/news/guidance-onzika-virus/. Accessed October 13, 2016.
69. McClure M. FDA recommendations and analyses supporting US HCT/P safety. Zika Virus Symposium: Blood and HCT/P Safety. June 10, 2016; Washington, DC.
70. European Centre for Disease Prevention and Control. Zika virus and safety of substances of human origin-A guide for preparedness activities in Europe. Stockholm, Sweden: ECDC; 2016. http://ecdc.europa.eu/en/publications/publications/zika-virus-safety-of-substances-of-human-origin.pdf. Accessed August 21, 2016.
71. Menitove J, Bennett JL, Tomasulo P, Katz LM. How safe is safe enough, who decides and how: from a zero-risk paradigm to risk-based decision making. Transfusion. 2014;54(3, pt 2):753-757.
72. Alliance of Blood Operators. The risk-based decision-making framework. https://www.allianceofbloodoperators.org/abo-resources/risk-based-decisionmaking/rbdm-framework.aspx. Accessed August 21, 2016.
73. Germain M. Canadian approach: HQ risk analysis. AABB Zika Virus Symposium: Blood and HCTP/Safety. June 10, 2016; Washington, DC.